Balasa Dinverno & Foltz’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $581K | Buy |
9,426
+3,308
| +54% | +$209K | 0.04% | 183 |
|
|
2022
Q2 | $378K | Sell |
6,118
-686
| -10% | -$42.5K | 0.02% | 235 |
|
|
2022
Q1 | $404K | Sell |
6,804
-4,069
| -37% | -$260K | 0.03% | 222 |
|
|
2021
Q4 | $789K | Buy |
10,873
+2,641
| +32% | +$182K | 0.05% | 155 |
|
|
2021
Q3 | $575K | Buy |
8,232
+25
| +0.3% | +$1.76K | 0.04% | 180 |
|
|
2021
Q2 | $565K | Sell |
8,207
-1,917
| -19% | -$128K | 0.04% | 174 |
|
|
2021
Q1 | $654K | Buy |
10,124
+2,615
| +35% | +$169K | 0.05% | 152 |
|
|
2020
Q4 | $437K | Buy |
7,509
+720
| +11% | +$43.4K | 0.04% | 180 |
|
|
2020
Q3 | $429K | Sell |
6,789
-10,087
| -60% | -$699K | 0.04% | 168 |
|
|
2020
Q2 | $1.3M | Buy |
16,876
+4,049
| +32% | +$310K | 0.14% | 66 |
|
|
2020
Q1 | $959K | Buy |
12,827
+3,063
| +31% | +$212K | 0.12% | 84 |
|
|
2019
Q4 | $634K | Sell |
9,764
-1,068
| -10% | -$69.5K | 0.07% | 135 |
|
|
2019
Q3 | $687K | Sell |
10,832
-121
| -1% | -$7.91K | 0.08% | 117 |
|
|
2019
Q2 | $740K | Buy |
10,953
+2,708
| +33% | +$178K | 0.09% | 110 |
|
|
2019
Q1 | $536K | Buy |
8,245
+848
| +11% | +$56.4K | 0.06% | 126 |
|
|
2018
Q4 | $463K | Sell |
7,397
-7,672
| -51% | -$536K | 0.06% | 134 |
|
|
2018
Q3 | $1.16M | Sell |
15,069
-878
| -6% | -$66.3K | 0.13% | 64 |
|
|
2018
Q2 | $1.13M | Sell |
15,947
-4,894
| -23% | -$346K | 0.16% | 59 |
|
|
2018
Q1 | $1.57M | Sell |
20,841
-1,002
| -5% | -$79.7K | 0.24% | 40 |
|
|
2017
Q4 | $1.56M | Sell |
21,843
-476
| -2% | -$36.1K | 0.23% | 44 |
|
|
2017
Q3 | $1.81M | Buy |
22,319
+3,311
| +17% | +$253K | 0.28% | 33 |
|
|
2017
Q2 | $1.34M | Buy |
19,008
+6,698
| +54% | +$446K | 0.22% | 40 |
|
|
2017
Q1 | $836K | Buy |
12,310
+2,608
| +27% | +$183K | 0.14% | 63 |
|
|
2016
Q4 | $695K | Sell |
9,702
-2,672
| -22% | -$199K | 0.12% | 74 |
|
|
2016
Q3 | $979K | Buy |
12,374
+1,167
| +10% | +$94.8K | 0.18% | 52 |
|
|
2016
Q2 | $935K | Buy |
11,207
+1,255
| +13% | +$111K | 0.17% | 49 |
|
|
2016
Q1 | $914K | Sell |
9,952
-3,329
| -25% | -$300K | 0.16% | 44 |
|
|
2015
Q4 | $1.34M | Buy |
13,281
+341
| +3% | +$35.5K | 0.23% | 32 |
|
|
2015
Q3 | $1.27M | Buy |
12,940
+544
| +4% | +$60.4K | 0.22% | 32 |
|
|
2015
Q2 | $1.45M | Buy |
12,396
+2,476
| +25% | +$271K | 0.24% | 28 |
|
|
2015
Q1 | $973K | Buy |
9,920
+262
| +3% | +$26.6K | 0.14% | 43 |
|
|
2014
Q4 | $910K | Buy |
9,658
+229
| +2% | +$23.7K | 0.13% | 47 |
|
|
2014
Q3 | $1M | Buy |
9,429
+124
| +1% | +$12.1K | 0.15% | 41 |
|
|
2014
Q2 | $771K | Buy |
9,305
+337
| +4% | +$26.2K | 0.09% | 47 |
|
|
2014
Q1 | $635K | Buy |
8,968
+629
| +8% | +$49.3K | 0.08% | 55 |
|
|
2013
Q4 | $626K | Buy |
8,339
+120
| +1% | +$8.36K | 0.09% | 52 |
|
|
2013
Q3 | $517K | Buy |
8,219
+160
| +2% | +$9.56K | 0.09% | 59 |
|
|
2013
Q2 | $413K | Buy |
+8,059
| New | +$420K | 0.07% | 64 |
|
Other funds holding GILD
Balasa Dinverno & Foltz's GILD Position: Q3 2022 in Review
Balasa Dinverno & Foltz increased its Gilead Sciences (GILD) stake by 54% in Q3 2022, buying an estimated $209K and bringing the position to 9,426 shares worth $581K. The position accounts for 0.04% of the portfolio, ranked #183.
Balasa Dinverno & Foltz first reported a position in GILD in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.81M in Q3 2017. 1,603 funds tracked by Wall St. Rank hold GILD as of Q3 2022.
- Balasa Dinverno & Foltz held 9,426 shares of Gilead Sciences worth $581K as of Q3 2022.
- Balasa Dinverno & Foltz bought 3,308 Gilead Sciences shares in Q3 2022, an estimated $209K.
- Gilead Sciences made up 0.04% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #183 holding.
- Balasa Dinverno & Foltz first reported a position in Gilead Sciences in Q2 2013 and has held it in 38 quarters since.
- Balasa Dinverno & Foltz's Gilead Sciences position peaked at $1.81M in Q3 2017.
- 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.